Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the immune system to target a portion of the virus surface that is less variable.
How an earnings call comment from Al Sandrock propelled an appeals court’s reversal on a Biogen investor suit
The US Court of Appeals for the First Circuit yesterday reversed a lower court’s ruling on one specific claim linked to investor allegations that Biogen